Submit Your Article CMED MEACR meeting
An official publication of the Middle-Eastern Association for Cancer Research
Clinical Cancer Investigation Journal
ISSN Print: 2278-1668, Online: 2278-0513
ARTICLE
Year: 2023   |   Volume: 12   |   Issue: 1   |   Page: 43-47     View issue

Study of the Antitumor Activity of Selenium Nanoparticles


, , , , ,
Abstract

In the scientific literature, studies on the feasibility of using selenium nanoparticles in the development of pharmaceuticals are widely presented. The positive effects of selenium in the treatment of cancer, hepatitis C, thyroid disease, cardiovascular disease, asthma, and other diseases have been studied. This scientific paper presents the results of studies on the effect of selenium nanoparticles on the development of a cancerous tumor. The experiment was carried out on five groups of white laboratory mice, with group 1 (positive control) being healthy individuals; group 2 (negative control) - individuals infected with EPNT-5 cancer cells; group 3 (experiment) - infected individuals that received an injection of selenium nanoparticles; group 4 (experiment) - infected individuals that received an injection of selenium nanoparticles and immunoglobulin imG; group 5 (experiment) - infected individuals who received an injection of immunoglobulin imG. During the experiment, the development of the disease and the behavior of laboratory animals were monitored. After 4 weeks, blood was taken for a general and biochemical test, and the masses of the internal organs of laboratory mice were also examined.

Cite this article
Vancouver
Maslyakova AR, Magomedova SA, Romantsov IN, Nurbagandov SM, Bulovin MN, Podobin OR. Study of the Antitumor Activity of Selenium Nanoparticles. Clin Cancer Investig J. 2023;12(1):43-7. https://doi.org/10.51847/yt84akUBr0
APA
Maslyakova, A. R., Magomedova, S. A., Romantsov, I. N., Nurbagandov, S. M., Bulovin, M. N., & Podobin, O. R. (2023). Study of the Antitumor Activity of Selenium Nanoparticles. Clinical Cancer Investigation Journal, 12(1), 43-47. https://doi.org/10.51847/yt84akUBr0

Downloads: 177

Views: 1601
Copyright © 2024 Clinical Cancer Investigation Journal, All rights are reserved and for all open access contents, the Creative Commons licensing terms apply.
Online since 01 December, 2011
Creative Commons License 
ISSN Print: 2278-1668, Online: 2278-0513